Coloplast A/S

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: DK0060448595
DKK
581.20
433.64 (293.87%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

289.23 k

Shareholding (Mar 2024)

FII

0.00%

Held by 2 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

DKK 121,369 Million ()

stock-summary
P/E

29.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

3.64%

stock-summary
Debt Equity

1.04

stock-summary
Return on Equity

24.43%

stock-summary
Price to Book

7.53

Revenue and Profits:
Net Sales:
6,958 Million
(Quarterly Results - Jun 2025)
Net Profit:
805 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
227.05%
0%
227.05%
6 Months
279.15%
0%
279.15%
1 Year
384.54%
0%
384.54%
2 Years
524.95%
0%
524.95%
3 Years
672.87%
0%
672.87%
4 Years
790.73%
0%
790.73%
5 Years
707.22%
0%
707.22%

Coloplast A/S for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
8.49%
EBIT Growth (5y)
5.43%
EBIT to Interest (avg)
27.35
Debt to EBITDA (avg)
1.46
Net Debt to Equity (avg)
1.34
Sales to Capital Employed (avg)
1.11
Tax Ratio
30.03%
Dividend Payout Ratio
142.56%
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
40.03%
ROE (avg)
47.24%
Valuation key factors
Factor
Value
P/E Ratio
29
Industry P/E
Price to Book Value
7.47
EV to EBIT
19.10
EV to EBITDA
16.23
EV to Capital Employed
3.71
EV to Sales
5.23
PEG Ratio
NA
Dividend Yield
3.59%
ROCE (Latest)
19.44%
ROE (Latest)
26.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 1.06% vs 12.72% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -36.81% vs 0.16% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,958.00",
          "val2": "6,885.00",
          "chgp": "1.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,232.00",
          "val2": "2,185.00",
          "chgp": "2.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "190.00",
          "val2": "229.00",
          "chgp": "-17.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-67.00",
          "val2": "-55.00",
          "chgp": "-21.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "805.00",
          "val2": "1,274.00",
          "chgp": "-36.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "271.50%",
          "val2": "269.70%",
          "chgp": "0.18%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2024 is 10.33% vs 8.51% in Sep 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2024 is 5.62% vs 1.64% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "27,030.00",
          "val2": "24,500.00",
          "chgp": "10.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "8,700.00",
          "val2": "7,858.00",
          "chgp": "10.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "882.00",
          "val2": "719.00",
          "chgp": "22.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-89.00",
          "val2": "-33.00",
          "chgp": "-169.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "5,052.00",
          "val2": "4,783.00",
          "chgp": "5.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "274.10%",
          "val2": "277.10%",
          "chgp": "-0.30%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
6,958.00
6,885.00
1.06%
Operating Profit (PBDIT) excl Other Income
2,232.00
2,185.00
2.15%
Interest
190.00
229.00
-17.03%
Exceptional Items
-67.00
-55.00
-21.82%
Consolidate Net Profit
805.00
1,274.00
-36.81%
Operating Profit Margin (Excl OI)
271.50%
269.70%
0.18%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 1.06% vs 12.72% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -36.81% vs 0.16% in Jun 2024

Annual Results Snapshot (Consolidated) - Sep'24stock-summary
Sep'24
Sep'23
Change(%)
Net Sales
27,030.00
24,500.00
10.33%
Operating Profit (PBDIT) excl Other Income
8,700.00
7,858.00
10.72%
Interest
882.00
719.00
22.67%
Exceptional Items
-89.00
-33.00
-169.70%
Consolidate Net Profit
5,052.00
4,783.00
5.62%
Operating Profit Margin (Excl OI)
274.10%
277.10%
-0.30%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Sep 2024 is 10.33% vs 8.51% in Sep 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Sep 2024 is 5.62% vs 1.64% in Sep 2023

stock-summaryCompany CV
About Coloplast A/S stock-summary
stock-summary
Coloplast A/S
Pharmaceuticals & Biotechnology
Coloplast A/S is a Denmark-based company active within the healthcare sector. It is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The Company supplies products to hospitals, institutions as well as wholesalers and pharmacies.
Company Coordinates stock-summary
Company Details
Holtedam 1-3 , HUMLEBAEK None : 3050
stock-summary
Tel: 45 4911111145 4911 3376
stock-summary
Registrar Details